Skip to main content

Table 1 SEER-Medicare study population (1993–2005): soft tissue sarcoma patients (n = 3,480) and non-cancer controls (n = 3,480)

From: Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

  Cancer Non-cancer
n % N %
Age in years
 65–69 475 13.7 549 15.8
 70–74 825 23.7 836 24.0
 75–79 880 25.3 853 24.5
 80–84 744 21.4 715 20.6
 85+ 556 16.0 527 15.1
Race
 Black 300 8.6 301 8.7
 White 2,967 85.3 2,945 84.6
 Other/unknown race 213 6.1 234 6.7
Sex
 Female 1,843 53.0 1,972 56.7
 Male 1,637 47.0 1,508 43.3
STS subtype
 Sarcoma NOS 1,422 40.9 na na
 GIST 845 24.3 na na
 Leiomyosarcoma 264 7.6 na na
 Maligant fibrous histiocytoma 224 6.4 na na
 Angiosarcoma 184 5.3 na na
 Liposaroma 136 3.9 na na
 Nerve sheath tumor 118 3.4 na na
 Fibrosarcoma 64 1.8 na na
 Synovial Sarcoma 49 1.4 na na
 Osteosarcoma 44 1.3 na na
 Rhabdomyosarcoma 25 0.7 na na
 Chondrosarcoma 25 0.7 na na
 Dermatofibrosaroma 22 0.6 na na
 Ewing sarcoma 19 0.5 na na
 Maligant hemangiopericytoma 15 0.4 na na
 Clear cell sarcoma <11 0.3 na na
 Myxosarcoma <11 0.2 na na
 Alveolar soft part <11 0.1 na na
 Maligant granular cell tumor <11 0.1 na na
 Maligant giant cell tumor <11 0.0 na na
Primary site
 Connective/subcutaneous tissue 1,217 35.0 na na
 Digestive system 1,107 31.8 na na
 Respiratory system 279 8.0 na na
 Breast 178 7.7 na na
 Other non-epithelial skin 167 5.1 na na
 Female genital system 160 4.8 na na
 Urinary system 105 4.6 na na
 Other and unknown 267 3.0 na na
Stage
 Unstaged 482 13.9 na na
 Localized 1,482 42.6 na na
 Regional 800 23.0 na na
 Distant 716 20.5 na na
  1. Per SEER Medicare data use agreement, cell sizes <11 cannot be displayed.
  2. na not applicable.